RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
Pathways to Parity Program Approved for $250K PCORI Engagement Award
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Clinical Trials Day: A Historic Review of the First Clinical Trial
Down syndrome collaborators now published in Alzheimer’s and Dementia
LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab
Study: Medicare, Medicaid, and Dual Enrollment for Adults with Intellectual and Developmental Disabilities.
Message from the CEO: a look ahead to 2024
Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment
Study: Use of Medicaid by Adults with Down Syndrome
LuMind IDSC statement on FDA approval of Leqembi
Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome
LuMind IDSC Statement re: Donanemab Phase 3 Results
Important progress in the treatment of sleep apnea and Down syndrome
Hope and Action for Down syndrome Alzheimer’s research on WDSD 2023
Fierce Biotech article highlights dearth of inclusion in Alzheimer’s research
With support from Lilly, LuMind IDSC launches key research and awareness activities to advance Down syndrome research
Results from “Challenges of Caregiving” Survey Published in Research Journal
New Year Greetings from Hampus Hillerstrom
Statement on accelerated approval of Leqembi to treat mild-stage Alzheimer’s disease in the general population
Impact Report 2022
New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque
DS-CTN Data and Safety Monitoring Board (DSMB)
Lecanemab: New Treatment for Alzheimer’s Disease
NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability
Why is Down syndrome research important?
Potential New Therapy for Adults with Down Syndrome
LIFE-DSR: up close and personal with John
Caregivers Evaluate Independence in Individuals with Down Syndrome
Report of the Neuroatypical Conditions Expert Consultative Panel
Results from T21RS’s COVID-19 International Survey on Vaccination of Individuals with DS
Five Recent Down Syndrome Research Data Articles to Stay Up to Date
Publication Illustrates Need for Therapies to Address Immune Aging in Down Syndrome
LuMind IDSC Statement on CMS Proposed Coverage for Anti-Amyloid AD Drugs
LuMind IDSC, NDSS and NTG Urge the Advisory Council to Take Action on the Needs of the DS Community
LuMind IDSC and Dr. Nicole White Publish: Parental Perspectives on Research for Down Syndrome
LuMind IDSC and Team of Experts Publish Article on Aging with DS and the Future of Research
Expert Chat: A Conversation with Dr. Nicole White
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
A New Perspective on The Aduhelm Controversy
LuMind IDSC signs on to NTG statement re: Aduhelm
Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs
FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study
LuMind IDSC Supported the T21RS COVID-19 Initiative’s International Survey on Patients with COVID-19 and Down Syndrome
Findings Released for Ongoing Study of Clinical Trial Participation by the Down Syndrome Community
LuMind IDSC is Excited About a New Publication in the Journal of Patient-Reported Outcomes
LIFE-DSR Natural History Study Blood Biomarker Data Shared at CTAD
LuMind IDSC Acknowledged by T21RS For Work on COVID-19 Survey
myDSC Webinar – Fighting Alzheimer’s Disease in Down Syndrome: There is Hope!
The LuMind IDSC Foundation Partners with Eli Lilly and Company to Measure Blood Biomarkers in LIFE-DSR Natural History Study
LuMind IDSC and NDSS Submit Joint Recommendations for Advancing NIH-Funded Down Syndrome Research
T21RS Publishes Initial Results of COVID-19 and Down Syndrome Survey and Seeks More Participants
National Down Syndrome Organizations Combine Efforts to Publish Q&A on COVID-19 and Down Syndrome
A Memory Drug for Down Syndrome?
$60M in NIH INCLUDE Funding for Down Syndrome Research in 2020
Clinical Trial Volunteers Give The Gift That Keeps On Giving
Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab
Clinicians Answer Additional Medical Questions From LuMind IDSC Research Rally Panel Q&A
LIFE-DSR Study – Why Natural History Studies Are Important on the Path to New Treatments
Cerveau Technologies, Inc. Announces Partnership with LuMind IDSC to Expand LIFE DSR Study
LuMind Research Down Syndrome Foundation Launches the Down Syndrome Clinical Trials Network
Published results on the Roche Clinical Trials for CLEMATIS expected in the first half of 2019
New Trans-NIH INCLUDE Project for Down Syndrome will provide up to $261M Over 5 Years
Historic ~65% increase for NIH Down syndrome research
Increased Commitment to Down Syndrome Research Included in 2018 Omnibus Spending Bill
LuMind IDSC Foundation
110 Winn Street – Suite 105
Woburn, MA 01801
Phone: 781-825-1300
LuMindIDSC@LuMindIDSC.org
© 2024 LuMind IDSC Foundation.
